|
Sept. 12, 2005 |
|
|
Dec. 17, 2018 |
|
|
jRCT1080220086 |
Post marketing study of sivelestat sodium hydrate for acute lung injury associated with systemic inflammatory response syndrome |
|
| version: date: |
Ono Pharmaceutical Co., Ltd. |
||
06-6263-5670 |
||
Interventional |
||
Open study |
||
4 |
||
Male and female patients with ALI associated with SIRS aged over 18 years old are included. |
||
| 18age old over | ||
| No limit | ||
Both |
||
Acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS) |
||
investigational material(s) |
||
Efficacy and safety |
||
| ONO PHARMACEUTICAL CO.,LTD. | |
| JapicCTI-050088 | |